Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.5.2519

Quality Control Usage in High-Density Microarrays Reveals Differential Gene Expression Profiles in Ovarian Cancer  

Villegas-Ruiz, Vanessa (Experimental Oncology Laboratory, Research Department, National Institute of Pediatrics, Institute of Ophthalmology, "Conde de Valenciana")
Moreno, Jose (Research Direction, Juarez Hospital of Mexico)
Jacome-Lopez, Karina (Experimental Oncology Laboratory, Research Department, National Institute of Pediatrics, Institute of Ophthalmology, "Conde de Valenciana")
Zentella-Dehesa, Alejandro (Medicine Genomic and Environmental Toxicology Department, Biomedical Research Institute, UNAM)
Juarez-Mendez, Sergio (Experimental Oncology Laboratory, Research Department, National Institute of Pediatrics, Institute of Ophthalmology, "Conde de Valenciana")
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.5, 2016 , pp. 2519-2525 More about this Journal
Abstract
There are several existing reports of microarray chip use for assessment of altered gene expression in different diseases. In fact, there have been over 1.5 million assays of this kind performed over the last twenty years, which have influenced clinical and translational research studies. The most commonly used DNA microarray platforms are Affymetrix GeneChip and Quality Control Software along with their GeneChip Probe Arrays. These chips are created using several quality controls to confirm the success of each assay, but their actual impact on gene expression profiles had not been previously analyzed until the appearance of several bioinformatics tools for this purpose. We here performed a data mining analysis, in this case specifically focused on ovarian cancer, as well as healthy ovarian tissue and ovarian cell lines, in order to confirm quality control results and associated variation in gene expression profiles. The microarray data used in our research were downloaded from ArrayExpress and Gene Expression Omnibus (GEO) and analyzed with Expression Console Software using RMA, MAS5 and Plier algorithms. The gene expression profiles were obtained using Partek Genomics Suite v6.6 and data were visualized using principal component analysis, heat map, and Venn diagrams. Microarray quality control analysis showed that roughly 40% of the microarray files were false negative, demonstrating over- and under-estimation of expressed genes. Additionally, we confirmed the results performing second analysis using independent samples. About 70% of the significant expressed genes were correlated in both analyses. These results demonstrate the importance of appropriate microarray processing to obtain a reliable gene expression profile.
Keywords
High density microarrays; gene expression profiles; quality control; ovarian cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Burgoon LD, Eckel-Passow JE, Gennings C, et al (2005). Protocols for the assurance of microarray data quality and process control. Nucleic Acids Res, 33, e172.   DOI
2 Cai SY, Yang T, Chen Y, et al (2015). Gene expression profiling of ovarian carcinomas and prognostic analysis of outcome. J Ovarian Res, 8, 50.   DOI
3 Chang C, Wang J, Zhao C, et al (2011). Maximizing biomarker discovery by minimizing gene signatures. BMC Genomics, 12 Suppl 5, S6.
4 Bicaku E, Xiong Y, Marchion DC, et al (2012). In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer, 106, 1967-75.   DOI
5 Brazma A, Parkinson H, Sarkans U, et al (2003). ArrayExpress--a public repository for microarray gene expression data at the EBI. Nucleic Acids Res, 31, 68-71.   DOI
6 Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74.   DOI
7 Dinalankara W, Bravo HC (2015). Gene expression signatures based on variability can robustly predict tumor progression and prognosis. Cancer Inform, 14, 71-81.
8 Edgar R, Domrachev M, Lash AE (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res, 30, 207-10.   DOI
9 Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70.   DOI
10 Heyn H, Esteller M (2012). DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet, 13, 679-92.   DOI
11 Juarez-Mendez S, Zentella-Dehesa A, Villegas-Ruiz V, et al (2013). Splice variants of zinc finger protein 695 mRNA associated to ovarian cancer. J Ovarian Res, 6, 61.   DOI
12 Ma XJ, Dahiya S, Richardson E, et al (2009). Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res, 11, R7.   DOI
13 McCall MN, Murakami PN, Lukk M, et al (2011). Assessing affymetrix GeneChip microarray quality. BMC Bioinformatics, 12, 137.   DOI
14 Sun QL, Zhao CP, Wang TY, et al (2015). Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene, 572, 79-86.   DOI
15 Zakharkin SO, Kim K, Mehta T, et al (2005). Sources of variation in Affymetrix microarray experiments. BMC Bioinformatics, 6, 214.   DOI
16 Horikawa N, Baba T, Matsumura N, et al (2015). Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients. BMC Cancer, 15, 739.   DOI
17 Irizarry RA, Bolstad BM, Collin F, et al (2003). Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res, 31, e15.   DOI
18 Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96.   DOI
19 Knudsen S, Hother C, Gronbaek K, et al (2015). Development and blind clinical validation of a microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL. PLoS One, 10, e0115538.   DOI
20 Kolesnikov N, Hastings E, Keays M, et al (2015). ArrayExpress update--simplifying data submissions. Nucleic Acids Res, 43, D1113-6.   DOI
21 Li MH, Fu SB, Xiao HS (2015). Genome-wide analysis of microRNA and mRNA expression signatures in cancer. Acta Pharmacol Sin, 36, 1200-11.   DOI
22 Placa JR, Bueno Rde B, Pinheiro DG, et al (2015). Gene expression analysis of laryngeal squamous cell carcinoma. Genom Data, 5, 9-12.   DOI
23 Panteris E, Swift S, Payne A, et al (2007). Mining pathway signatures from microarray data and relevant biological knowledge. J Biomed Inform, 40, 698-706.   DOI
24 Parkinson H, Sarkans U, Shojatalab M, et al (2005). ArrayExpress--a public repository for microarray gene expression data at the EBI. Nucleic Acids Res, 33, D553-5.   DOI
25 Pepper SD, Saunders EK, Edwards LE, et al (2007). The utility of MAS5 expression summary and detection call algorithms. BMC Bioinformatics, 8, 273.   DOI
26 Quackenbush J (2001). Computational analysis of microarray data. Nat Rev Genet, 2, 418-27.   DOI
27 Rocca-Serra P, Brazma A, Parkinson H, et al (2003). ArrayExpress: a public database of gene expression data at EBI. C R Biol, 326, 1075-8.   DOI
28 Rong G, Kang H, Wang Y, et al (2013). Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs). PLoS One, 8, e70960.   DOI
29 Seo J, Gordish-Dressman H, Hoffman EP (2006). An interactive power analysis tool for microarray hypothesis testing and generation. Bioinformatics, 22, 808-14.   DOI
30 Sonachalam M, Shen J, Huang H, et al (2012). Systems biology approach to identify gene network signatures for colorectal cancer. Front Genet, 3, 80.